The information Medicare plans to require providers submit to its own homegrown registry as a condition of administration of monoclonal antibody anti-amyloid treatments for Alzheimer’s should make it relatively easy for physicians to participate, but may ultimately make it harder for the US Centers for Medicare and Medicaid services to get critical answers about the effects of the treatments, experts told the Pink Sheet.
Key Takeaways
- CMS’s registry requirements for Alzheimer’s drugs seem designed to limit the burden on physicians and ease participation.
The Centers for Medicare and Medicaid released more details about the information it will require in its registry, as well...
